8-KItem 7.01 · Reg FD Disclosure
Cencora reaffirms fiscal 2026 adjusted EPS guidance
Filed with the SEC on · Summarized by InvestorsBot
Cencora said certain Walgreens volume serviced outside its prime vendor agreement began moving away from the company on July 1, 2026; the prime vendor agreement remains unchanged and represents most of Cencora’s Walgreens business. The company reaffirmed its fiscal 2026 adjusted diluted EPS guidance of $17.75 to $17.95, consistent with its August 5 commentary on fourth-quarter U.S. Healthcare Solutions expectations.